Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
03 nov. 2022 16h01 HE
|
Fate Therapeutics, Inc.
FT596+R Enrollment Ongoing in Three-dose Escalation Cohort for R/R BCL; Activating Community Sites for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive BCL Positive Feedback...
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting
03 nov. 2022 09h00 HE
|
Fate Therapeutics, Inc.
Clinical Presentations to Include Initial Clinical Data of FT576 BCMA-targeted CAR NK Cell Product Candidate for Multiple Myeloma and FT819 CD19-targeted CAR T-cell Product Candidate for B-cell...
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
24 oct. 2022 16h01 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting
05 oct. 2022 08h00 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics to Participate at Upcoming September Investor Conferences
02 sept. 2022 08h00 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development...
Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8αβ T Cells from TCR-CAR+ Induced Pluripotent Stem Cells
09 août 2022 08h00 HE
|
Fate Therapeutics, Inc.
TCR-CAR+ iPSC-derived CD8αβ T Cells Induced Complete and Durable Responses In Vivo in Systemic Leukemia Model Cell-surface Markers, Gene Transcription Profile, and In Vivo Anti-tumor Activity of...
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
03 août 2022 16h01 HE
|
Fate Therapeutics, Inc.
FT596+R Enrollment Ongoing in Multi-dose, Multi-cycle Cohorts for R/R BCL; Initiated Study Start-up for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive BCL FT516 RMAT...
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
25 juil. 2022 16h01 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer
30 juin 2022 16h01 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell Cancer Immunotherapies
28 juin 2022 07h00 HE
|
Fate Therapeutics, Inc.
ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration Expanded Partnership Enables Development of both CAR NK and CAR T-cell Collaboration Candidates for Solid...